Placenta previa cases are one of the difficult groups of patients to manage in modern obstetrics. When the literature is evaluated extensively, no clear information can be seen especially in terms of hospitalization time. Inpatient follow-up of this patients has negative effects like hospital infections in terms of the patient, workload in terms of health personnel and financial losses in terms of the country's economy. Placenta previa cases are complicated patients in which generalizations cannot be easily performed and they should be monitored at third level hospitals. In addition, care should be personalized considering the many reasons. In this study, placenta previa cases will be followed up at 28th gestational week and evaluated at 32nd week by vaginal ultrasonography and MRI and this follow-up will continue until delivery. Thus, in this study, it was aimed to determine the parameters that would allow systematic personalization of health service in this particular patient group by making risk assessment of placenta previa cases.
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Diagnostic
- Masking: None (Open Label)
- Study Primary Completion Date: February 1, 2020
- Diagnostic Test: Vaginal Ultrasonography
- Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography for invasion anomaly and preterm birth.
- Diagnostic Test: Magnetic Resonance Imaging
- Placenta previa cases will be evaluated at 32nd week by MRI for invasion anomaly and preterm birth.
Arms, Groups and Cohorts
- Experimental: Placenta Previa
- Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography and MRI.
Clinical Trial Outcome Measures
- The number of placental invasion pathologies
- Time Frame: 1 day
- Placental invasion pathologies detected during delivery will be evaluated.
- The number of preterm birth
- Time Frame: 1 day
- The relation between preterm birth and placental invasion pathologies will be assessed.
Participating in This Clinical Trial
- Monitoring of placenta previa – To apply before the 28th week – To have a low-risk second trimester screening test – No malformation detected in the anomaly screening Exclusion Criteria:
- Multiple pregnancies – Pregnancy complicated with preeclampsia – Pregnancy complicated by gestational hypertension – Pregnancy complicated by gestational diabetes mellitus
Gender Eligibility: Female
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- Ege University
- Provider of Information About this Clinical Study
- Principal Investigator: Sabahattin Anıl Arı, Principal Investigator – Ege University
- Overall Official(s)
- Sabahattin a Arı, MD, Principal Investigator, Ege University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.